On the recordSeptember 21, 2016
Our bill is the product of consultations with a wide range of stakeholders, as Senator Feinstein has mentioned, and it would give the FDA broader oversight.
Source
congress.govEditor's note · Context
Collins emphasizes stakeholder involvement in creating the bill for FDA oversight.
Share
More from Susan Collins
Jul 7, 2026
These allegations are appalling. Nevertheless, it is not up to me to choose the Democratic nominee for Senate.
Other voices in this conversation
